ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO678

Reduced Dose Non-Cyclical Oral Cyclophosphamide and Prednisolone for Membranous Nephropathy

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Subramaniam, Karppagavalli, KMCH, Coimbatore, Tamilnadu, India
  • Ponnusamy, Srimathi, KMCH, Coimbatore, Tamilnadu, India
  • Veerasamy, Mangalakumar, KMCH, Coimbatore, Tamilnadu, India

Calcineurin inhibitors, rituximab and cyclic steroid & cyclophosphamide are the main therapeutic options in membranous nephropathy (MN). We describe the effect of non-cyclical reduced dose oral cyclophosphamide/ prednisolone (nCCP) in this group.


Patients were given oral cyclophosphamide (1.5mg/kg body weight/day) and prednisolone (0.5mg/kg body weight/day) for 3 months. At 3 months cyclophosphamide was stopped and prednisolone was tapered over the ensuing 4-7 weeks at a decremental rate of 5mg/week.


Patient characteristics are described in table 1. Remission rates are given in figure 1 . 3 patients experienced major adverse events (pneumonia -2, zoster-1, hemorrhagic cystitis-1).


nCCP regime appears to have comparable effect in inducing proteinuria remission at 6 & 12 months in this retrospective study and it was achieved using lower dose of cyclophosphamide. The latter may help to reduce cumulative cyclophosphamide related toxicities. This regime avoids pulse steroid infusion without losing the efficacy. Corticosteroid and cyclophosphamide were used simultaneously and whether this could help to use lower doses of cyclophosphamide merits further evaluation. Despite using lower dose of cyclophosphamide (1.5mg/kg as opposed to 2mg/kg in RI-CYCLO study) 1 of our patients developed hemorrhagic cystitis raises the important safety question about the use of cytotoxic agents.

Patient characteristics (Total no = 21)
Age in years, mean (SD)43.7(11)
Sex - Male, n (%)12(57)
DM, n (%)2(9.5%)
HT, n (%)11(52)
Weight (kg), mean (SD)66.8(10.7)
Systolic BP (mmHg), mean (SD)127.8(16)
Diastolic BP (mmHg), mean (SD)76.6(8)
Serum creatinine (mg/dL), mean (SD0.7(0.23)
Urine protein/creatinine ratio, mean (SD)7(3.4)
Serum albumin (g/dL), mean (SD)2.2(0.5)
Total cholesterol (mg/dL), mean (SD)316(95)
Serum anti-PLA2R antibody positivity, n(%)14(66.7)